摘要
目的 研究沙库巴曲/缬沙坦联合比索洛尔在慢性心力衰竭治疗中的临床疗效。方法 87例慢性心力衰竭患者,根据治疗方法不同分为治疗组(44例)和对照组(43例)。对照组患者在常规治疗基础上应用依那普利联合比索洛尔治疗,治疗组患者在常规治疗基础上应用沙库巴曲/缬沙坦联合比索洛尔治疗。观察比较两组患者的临床疗效、治疗前后心功能指标(6 min步行距离、左室舒张末期内径、左室射血分数、N-末端脑钠肽前体水平)及治疗3个月主要不良心血管事件(恶性心律失常、心源性休克)发生情况、再住院率,并分析两组患者不良反应发生情况。结果 治疗组患者的治疗总有效率为95.45%,对照组患者的治疗总有效率为81.40%,治疗组患者的治疗总有效率显著高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者的6 min步行距离、左室舒张末期内径、左室射血分数、N-末端脑钠肽前体水平均优于治疗前,且治疗组优于对照组,差异均具有统计学意义(P<0.05)。治疗组患者治疗3个月恶性心律失常、心源性休克发生率及再住院率分别为4.5%、6.8%、18.2%,均低于对照组的18.6%、23.3%、37.2%,差异具有统计学意义(P<0.05)。两组患者出现干咳、高血钾症低血压及心源性休克等,减量及对症治疗后好转,未出现血管性水肿。结论 沙库巴曲/缬沙坦联合比索洛尔治疗慢性心力衰竭疗效显著,明显改善心力衰竭患者病情,降低再住院率和减少不良心血管事件,且通过联合口服方式依从性高,适合基层医院临床推广应用。
Objective To study the clinical efficacy of sacubitril/valsartan and bisoprolol in the treatment of chronic heart failure.Methods A total of 87 chronic heart failure patients were divided into treatment group(44 cases)and control group(43 cases)by different treatment methods.The control group was treated by enalapril combined with bisoprolol on the basis of conventional therapy,and the treatment group was treated by sacubitril/valsartan combined with bisoprolol on the basis of conventional therapy.The clinical efficacy,cardiac function indicators(6-min walking distance,left ventricular end diastolic diameter,left ventricular ejection fraction,N-terminal pro-brain natriuretic peptide)before and after treatment,occurrence of main adverse cardiovascular events(malignant arrhythmia,cardiogenic shock)after 3 months of treatment,rehospitalization rate were compared between the two groups,and the occurrence of adverse reactions were analyzed between the two groups.Results The total effective rate of treatment was 95.45%in the treatment group,which was 81.40%in the control group.The total effective rate of treat ment in the treatment group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the 6-min walking distance,left ventricular end diastolic diameter,left ventricular ejection fraction,N-terminal pro-brain natriuretic peptide in the two groups was better than those before treatment,and the treatment group was better than the control group.Their difference was statistically significant(P<0.05).After 3 months of treatment,the incidence of malignant arrhythmia and cardiogenic shock and rehospitalization rate were 4.5%,6.8%and 18.2%in the treatment group,which was lower than 18.6%,23.3%and 37.2%in the control group,and their difference was statistically significant(P<0.05).Patients in the two groups developed dry cough,hyperkalemia,hypotension,and cardiogenic shock.After reduction and symptomatic treatment,they improved without angioedema.Concl
作者
陈勇鹏
林晓周
CHEN Yong-peng;LIN Xiao-zhou(Jiexi County Mianhu Overseas Chinese Hospital,Jieyang 515438,China)
出处
《中国现代药物应用》
2020年第5期1-3,共3页
Chinese Journal of Modern Drug Application
